Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CAMOQUIN HYDROCHLORIDE vs ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Amodiaquine hydrochloride is a 4-aminoquinoline compound that acts as a blood schizonticide. It inhibits heme polymerase, leading to accumulation of toxic heme-iron complexes in the parasite's food vacuole, disrupting membrane function and parasite replication.
Chloroquine and primaquine: Chloroquine inhibits heme polymerase in malaria parasites, preventing conversion of toxic heme to hemozoin; primaquine disrupts mitochondrial function and generates reactive oxygen species, targeting hypnozoites and gametocytes.
Treatment of acute malaria caused by chloroquine-sensitive or chloroquine-resistant Plasmodium falciparum and other Plasmodium species,Treatment of uncomplicated malaria (FDA-approved),Off-label: intermittent preventive treatment of malaria in pregnancy (IPTp) in combination with sulfadoxine-pyrimethamine
Treatment of acute attacks of vivax malaria due to Plasmodium vivax,Radical cure of vivax malaria (elimination of hypnozoites),Suppression of malaria (prophylaxis) in areas with chloroquine-sensitive P. vivax
600 mg base (1 g salt) orally once weekly for prophylaxis; 600 mg base (1 g salt) initially followed by 600 mg base at 6, 24, and 48 hours for treatment of malaria.
Chloroquine phosphate 600 mg base (1 g salt) orally once daily for 2 days, then 300 mg base (500 mg salt) once daily for at least 2 weeks; plus primaquine phosphate 30 mg base orally once daily for 14 days.
Terminal elimination half-life ranges 9–21 days (mean ~14 days) due to extensive tissue binding; clinical context: steady-state achieved after 4–6 weeks, prolonged half-life allows weekly dosing for malaria prophylaxis.
Chloroquine: 40-60 days (terminal); Primaquine: 6-8 hours (terminal). Clinical context: chloroquine accumulates extensively, requiring prolonged monitoring for toxicity; primaquine, shorter half-life, once-daily dosing.
Primarily metabolized in the liver by CYP2C8 to the active metabolite desethylamodiaquine. Also undergoes N-oxidation and conjugation.
Chloroquine: hepatic metabolism via CYP2C8 and CYP3A4; primaquine: hepatic metabolism via CYP2D6 and other enzymes.
Primarily hepatic metabolism (approx. 60-70%) with metabolites excreted in bile and feces; renal excretion of unchanged drug accounts for <5% of the dose. Fecal elimination accounts for ~20-30% of the dose, with minor biliary contribution.
Renal: 70% (chloroquine as unchanged drug and metabolites), 20% (primaquine as metabolites); Fecal: ~10% (chloroquine); Biliary: minor for both.
Approximately 90% bound to plasma proteins, mainly albumin and alpha-1-acid glycoprotein.
Chloroquine: 50-65% bound to albumin; Primaquine: ~20% bound to albumin.
Mean Vd ~100–300 L/kg (extremely large due to extensive tissue sequestration, especially in erythrocytes and liver); indicates deep tissue distribution.
Chloroquine: Vd 100-200 L/kg (extensive tissue distribution); Primaquine: Vd 3-5 L/kg (moderate distribution). Clinical meaning: large Vd of chloroquine indicates deep tissue compartments with slow release.
Oral bioavailability is approximately 75–85% (first-pass metabolism limited).
Both: Oral bioavailability ~80-90% for chloroquine; ~90% for primaquine. No parenteral form for this combination.
No specific guidelines; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation.
For chloroquine: GFR 10-50: 50% dose; GFR <10: 25% dose. For primaquine: No adjustment required, but monitor for hemolysis in GFR <10 due to accumulation.
No specific guidelines; contraindicated in severe hepatic impairment (Child-Pugh class C) due to risk of toxicity.
For chloroquine: Child-Pugh A/B: no adjustment; Child-Pugh C: reduce dose by 50% or avoid. For primaquine: Child-Pugh A/B: no data, use with caution; Child-Pugh C: contraindicated due to risk of hemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficiency and impaired clearance.
5 mg base/kg (8.3 mg salt/kg) orally once weekly for prophylaxis; 10 mg base/kg (16.6 mg salt/kg) initially, followed by 5 mg base/kg at 6, 24, and 48 hours for treatment.
Chloroquine: 10 mg base/kg orally once daily for 2 days, then 5 mg base/kg once daily (max 300 mg base/day) for 2 weeks. Primaquine: 0.5 mg base/kg orally once daily for 14 days (max 30 mg base/day). Ensure G6PD screening before use.
Use with caution; consider lower initial doses and monitor for QT prolongation and neuropsychiatric effects due to age-related changes in clearance.
Use lower end of adult dose for chloroquine due to reduced renal function; adjust according to Cr Cl. For primaquine, monitor for G6PD deficiency and hemolysis; dose as per adult. Consider increased risk of QT prolongation with chloroquine.
Amodiaquine hydrochloride is associated with hepatotoxicity and agranulocytosis. Use is contraindicated in patients with previous adverse reactions to amodiaquine. Prolonged use for prophylaxis is not recommended due to risk of severe hepatic injury and blood dyscrasias.
Primaquine may cause hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Test for G6PD deficiency before starting therapy.
Monitor liver function tests; discontinue if signs of hepatotoxicity (elevated transaminases, jaundice). Risk of agranulocytosis, neutropenia; monitor CBC. Caution in patients with G6PD deficiency (risk of hemolysis). Can cause QT prolongation; avoid in patients with pre-existing QTc prolongation or with other QT-prolonging drugs. Reduce dose in severe hepatic impairment. Use in pregnancy only if potential benefit outweighs risk (no adequate studies).
Hemolytic anemia (especially G6PD deficiency), bone marrow suppression, prolonged QT interval, visual disturbances (retinopathy with chloroquine), methemoglobinemia, and severe hypersensitivity reactions.
Hypersensitivity to amodiaquine or other 4-aminoquinolines (e.g., chloroquine); history of hepatic disease or blood dyscrasias (e.g., agranulocytosis, neutropenia) associated with amodiaquine; concomitant use with hepatotoxic drugs or drugs known to cause agranulocytosis; patients with known G6PD deficiency (relative, use with caution).
G6PD deficiency (primaquine), known hypersensitivity to chloroquine or primaquine, porphyria, concurrent use of drugs with known hemolytic potential, pregnancy (based on risk-benefit), and severe liver or kidney disease.
No specific food restrictions; however, administration with fatty meals may enhance absorption. Avoid grapefruit juice due to potential CYP2C8 inhibition. Maintain adequate hydration and caloric intake.
No clinically significant food interactions reported. However, antacids containing magnesium or aluminum can reduce chloroquine absorption; separate administration by at least 4 hours. Grapefruit juice may increase chloroquine levels via CYP3A4 inhibition; avoid concurrent use.
First trimester: Amodiaquine (CAMOQUIN HYDROCHLORIDE) is not recommended due to limited data but animal studies show no teratogenicity at therapeutic doses. Second/third trimester: Generally considered safe for malaria treatment; no evidence of increased malformations. Overall risk category C: Risk cannot be ruled out.
In first trimester, chloroquine is generally considered low risk for major malformations, but primaquine is contraindicated due to risk of hemolytic anemia in G6PD-deficient fetuses. Second and third trimesters: chloroquine is safe, but primaquine should be avoided as fetal G6PD status is unknown.
Excreted in breast milk in small amounts. M/P ratio not established. Use with caution, especially in infants with G6PD deficiency. The WHO considers amodiaquine compatible with breastfeeding during malaria treatment.
Chloroquine is excreted into breast milk in low concentrations; M/P ratio is approximately 0.5-0.6. Primaquine is excreted in breast milk; M/P ratio not well established. Breastfeeding is generally considered safe if infant is G6PD normal, but caution is advised due to potential for hemolysis in G6PD-deficient infants.
No specific dose adjustment required in pregnancy; standard dosing recommended for malaria treatment (based on weight). Pharmacokinetic changes in pregnancy (increased volume of distribution) do not necessitate dose modification.
Chloroquine: No dose adjustment required; pharmacokinetics are not significantly altered. Primaquine: Contraindicated in pregnancy due to risk of hemolytic anemia in the fetus; no dose adjustment is applicable as it is not recommended.
Camoquin hydrochloride (amodiaquine) is an antimalarial agent related to chloroquine. It is active against erythrocytic stages of Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae. Not effective against exo-erythrocytic forms. Hepatic metabolism via CYP2C8; genetic variants may affect toxicity. Monitor for hepatotoxicity and agranulocytosis, especially with prolonged use. Contraindicated in patients with liver disease or history of psychosis. Use with caution in G6PD deficiency due to risk of hemolysis.
Combination of chloroquine and primaquine is used for radical cure of P. vivax and P. ovale malaria. Chloroquine is effective against blood-stage parasites; primaquine eradicates hypnozoites in the liver. Screen for G6PD deficiency before initiating primaquine to prevent hemolytic anemia. Concurrent use with hematotoxic drugs (e.g., dapsone) increases hemolysis risk. Contraindicated in G6PD-deficient patients, pregnancy, and breastfeeding unless no alternative. Monitor for QT prolongation, especially with electrolyte abnormalities or concurrent QT-prolonging agents.
Take exactly as prescribed; do not stop early even if feeling better.,May cause nausea; taking with food or milk can help reduce stomach upset.,Avoid alcohol while on this medication due to increased risk of hepatotoxicity.,Report any yellowing of skin or eyes, dark urine, severe fatigue, or unusual bleeding/bruising immediately.,Use effective contraception during treatment and for at least 1 month after the last dose.,Do not take with fever or other antimalarials unless directed by your physician.
Take with food or milk to reduce gastrointestinal upset.,Complete full course regardless of symptom resolution to prevent relapse.,Avoid alcohol during treatment due to risk of disulfiram-like reaction.,Report signs of hemolysis: dark urine, jaundice, pallor, fatigue (especially if G6PD deficient).,Do not take antacids containing magnesium or aluminum within 4 hours of chloroquine as they reduce absorption.,Seek medical attention for visual disturbances, QT prolongation symptoms (palpitations, syncope), or severe GI distress.,Use effective contraception during and for 1 month after treatment due to potential fetal harm from primaquine.
No interactions on record
"Alimemazine, a phenothiazine derivative with antihistaminergic and anticholinergic properties, may inhibit the metabolism of Primaquine, an antimalarial agent primarily metabolized by cytochrome P450 enzymes including CYP2D6 and CYP3A4. This interaction can lead to increased plasma concentrations of Primaquine, heightening the risk of dose-dependent adverse effects such as hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and methemoglobinemia. Clinically, patients may present with signs of oxidant stress, including hemoglobinuria and jaundice."
"Eliglustat, a CYP2D6 substrate and inhibitor, can increase the systemic exposure of primaquine, which is primarily metabolized by CYP2D6. This elevation in primaquine concentration may potentiate its QTc-prolonging effects, leading to an increased risk of torsades de pointes and other ventricular arrhythmias. Caution is advised, especially in patients with pre-existing cardiac conditions or electrolyte abnormalities."
"Primaquine, an antimalarial agent, can inhibit the cardiac potassium channel encoded by the hERG gene, leading to prolongation of the QTc interval. Ivabradine, a funny current (If) inhibitor used for chronic heart failure, also possesses a mild QTc-prolonging effect. Concomitant use increases the risk of excessive QTc prolongation, which may precipitate torsade de pointes and other ventricular arrhythmias, particularly in patients with underlying risk factors such as electrolyte disturbances or bradycardia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CAMOQUIN HYDROCHLORIDE vs ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE, answered by our medical review team.
CAMOQUIN HYDROCHLORIDE is a Antimalarial that works by Amodiaquine hydrochloride is a 4-aminoquinoline compound that acts as a blood schizonticide. It inhibits heme polymerase, leading to accumulation of toxic heme-iron complexes in the parasite's food vacuole, disrupting membrane function and parasite replication.. ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE is a Antimalarial that works by Chloroquine and primaquine: Chloroquine inhibits heme polymerase in malaria parasites, preventing conversion of toxic heme to hemozoin; primaquine disrupts mitochondrial function and generates reactive oxygen species, targeting hypnozoites and gametocytes.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CAMOQUIN HYDROCHLORIDE and ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE depend on the specific clinical indication. These are both Antimalarial agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CAMOQUIN HYDROCHLORIDE is: 600 mg base (1 g salt) orally once weekly for prophylaxis; 600 mg base (1 g salt) initially followed by 600 mg base at 6, 24, and 48 hours for treatment of malaria.. The standard adult dose of ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE is: Chloroquine phosphate 600 mg base (1 g salt) orally once daily for 2 days, then 300 mg base (500 mg salt) once daily for at least 2 weeks; plus primaquine phosphate 30 mg base orally once daily for 14 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CAMOQUIN HYDROCHLORIDE and ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CAMOQUIN HYDROCHLORIDE is classified as Category C. First trimester: Amodiaquine (CAMOQUIN HYDROCHLORIDE) is not recommended due to limited data but animal studies show no teratogenicity at therapeutic doses. Second/third trimester:. ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE is classified as Category D/X. In first trimester, chloroquine is generally considered low risk for major malformations, but primaquine is contraindicated due to risk of hemolytic anemia in G6PD-deficient fetuse. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.